Following the US Preventive Services Task Force (USPSTF) report in 2012 (2), there was a significantly reduced utilization of prostate cancer screening with prostate-specific antigen (PSA) testing, resulting in a lower overall detection of prostate cancer, but an unfortunate increase has emerged in the proportion of men presenting at advanced stages (1, 3–5). The gene discussed is KLK3; the disease is prostate cancer.